explore -WSS

explore

author：fashion 2025-10-01 15:00:13 - browse：463

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Gov. Ron DeSantis' push for 'civics' education: What does it look like?

WSS

Adele warns fans about throwing things at performers onstage

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Condition critical? Britain's beloved but battered National Health Service turns 75

Former New York Mayor de Blasio and wife announce separation, but not divorce

Brain MRIs reveal impact of 'toxic stress' on Black children

As health system earnings go up, health insurance stocks go down

Wikipedia

explore

focus

Drug repurposing or repositioning? The language matters

Empower primary care with adequate payments and technology

Affirmative action in medical school literally saved lives

Can gargling with Listerine treat gonorrhea of the mouth?

Hepatitis C has a cure — but many Americans still lack access to it

Warren pushes Witty on UnitedHealth's control over physicians

Jerome Adams on the need for new antivirals for Covid

Condition critical? Britain's beloved but battered National Health Service turns 75

Novavax promises a turnaround & Lilly roils the obesity market

EU moves toward latest gene techniques in food production to counter climate change, shortages

explore

Most antidepressants don't work on kids, teens, study finds

As billionaires fund anti

2 million sign

AltruBio raises $225 million to develop ulcerative colitis drug

Is it ever OK for doctors to lie to their patients?

Black vets could get higher VA benefits if race not used in lung test

hotspot

hotspot

Wikipedia

hotspot